MedTrace Logo

Use of Perioperative Pain Blocks In Urological Surgery

NCT04426500 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2024-03-12

Study results available
· View outcomes & findings →

Summary

The study team aims to prospectively compare Placebo (local administration), ultrasound-guided transversus abdominis plane (UTAP) blocks, and laparoscopic-guided transversus abdominis plane (LTAP) blocks in patients undergoing robotic surgery of the prostate and kidney. The study team expects to be able to equally efficiently administer the blocks using direct visualization and ultrasound guidance. The study team expects that a negative result would obviate the need for longer operative time by eliminating the need for the separate ultrasound guided block while a positive result would demonstrate the increased utility of preoperative ultrasound blocks in managing postoperative pain.

Conditions

  • Pain, Postoperative
  • Nerve Block
  • Robotic Surgical Procedures

Interventions

DRUG

Bupivacain

Direct injection of 0.25% bupivacaine into surgical wounds

DRUG

Ultrasound-guided transversus abdominus plane block

bilateral TAP using ultrasound guidance in prostatectomies

DRUG

Laparoscopic-guided transversus abdominus plane block

bilateral TAP using laparoscopic guidance in prostatectomies

Sponsors & Collaborators

Principal Investigators

  • Reza Mehrazin, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-11
Primary Completion
2021-02-13
Completion
2021-02-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04426500 on ClinicalTrials.gov